Toxicity of sorafenib: clinical and molecular aspects

Bibliography

• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47
   PubMed Web of Science ®Google Scholar
• Kolch W, Kotwaliwale A, Vass K, The role of Raf kinases in malignant transformation. Expert Rev Mol Med 2002;4:1-18
   PubMedGoogle Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U, Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30
   PubMed Web of Science ®Google Scholar
• Hoffmann K, Glimm H, Radeleff B, Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008;8:349
   PubMed Web of Science ®Google Scholar
• Hutson TE. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a phase III overview. Expert Rev Anticancer Ther 2007;7:1193-202
   PubMed Web of Science ®Google Scholar
• Strumberg D, Voliotis D, Moeller JG, Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002;40:580-1
   PubMedGoogle Scholar
• Porta C, Paglino C, Imarisio I, Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007;7:127-34
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67
   PubMed Web of Science ®Google Scholar
• Rahmani M, Davis EM, Bauer C, Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280:35217-27
   PubMed Web of Science ®Google Scholar
• Yu C, Bruzek LM, Meng XW, The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-9
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8
   PubMed Web of Science ®Google Scholar
• Salvatore G, De Falco V, Salerno P, BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623-9
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002;8:2255-7
   PubMed Web of Science ®Google Scholar
• Hennenberg M, Trebicka J, Stark C, Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009;157:258-70
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Sorafenib (nexavar): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/nexavar/H-690-PI-en.pdf. 17
   Google Scholar
• Lathia C, Lettieri J, Cihon F, Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-92
   PubMed Web of Science ®Google Scholar
• Awada A, Hendlisz A, Gil T, Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D, Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11:5472-80
   PubMed Web of Science ®Google Scholar
• Furuse J, Ishii H, Nakachi K, Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-65
   PubMed Web of Science ®Google Scholar
• Miller AA, Murry DJ, Owzar K, Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-5
   PubMed Web of Science ®Google Scholar
• Minami H, Kawada K, Ebi H, Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008;1492-8
   PubMed Web of Science ®Google Scholar
• Moore M, Hirte HW, Siu L, Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA, Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
   PubMed Web of Science ®Google Scholar
• Kupsch P, Henning BF, Passarge K, Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 2005;5:188-96
   PubMedGoogle Scholar
• Richly H, Henning BF, Kupsch P, Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73
   PubMed Web of Science ®Google Scholar
• Richly H, Schultheis B, Adamietz IA, Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 2009;45:579-87
   PubMed Web of Science ®Google Scholar
• Siu LL, Awada A, Takimoto CH, Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-51
   PubMed Web of Science ®Google Scholar
• Mross K, Steinbild S, Baas F, Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007;43:55-63
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, van Alphen RJ, Verweij J, Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94
   PubMed Web of Science ®Google Scholar
• Azad NS, Aragon-Ching JB, Dahut WL, Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15:1411-6
   PubMed Web of Science ®Google Scholar
• Blanchet B, Billemont B, Cramard J, Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 2009;49:1109-14
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Bukowski R, Elson P, Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008;19:265-8
   PubMed Web of Science ®Google Scholar
• Janusch M, Fischer M, Marsch W, The hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006;16:494-9
   PubMed Web of Science ®Google Scholar
• Yang CH, Lin WC, Chuang CK, Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-6
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Reilly LM, Gerami P, Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-61
   PubMed Web of Science ®Google Scholar
• Lee WJ, Lee JL, Chang SE, Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161(5):1045-51
   Google Scholar
• Robert C, Mateus C, Spatz A, Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009;60:299-305
   PubMed Web of Science ®Google Scholar
• Autier J, Escudier B, Wechsler J, Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-92
   PubMed Web of Science ®Google Scholar
• Arnault JP, Wechsler J, Escudier B, Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:e59-61
   PubMed Web of Science ®Google Scholar
• Kong HH, Cowen EW, Azad NS, Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007;56:171-2
   PubMed Web of Science ®Google Scholar
• Bennani-Lahlou M, Mateus C, Escudier B, Eruptive nevi associated with sorafenib treatment. Ann Dermatol Venereol 2008;135:672-4
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Novi M, Rinninella E, The pathogenic mechanisms of sorafenib-related diarrhea: preliminary results. Dig Liver Dis 2009;41:A14
   Google Scholar
• Wood L. Managing the side effects of sorafenib and sunitinib. Community Oncol 2006;3:558-62
   Google Scholar
• Benson AB III, Ajani JA, Catalano RB, Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-26
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6
   PubMed Web of Science ®Google Scholar
• Izzedine H, Ederhy S, Goldwasser F, Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-15
   PubMed Web of Science ®Google Scholar
• Eisen T, Oudard S, Szczylik C, Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008;100:1454-63
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Watanabe T, Nishida K, Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004;114:937-43
   PubMed Web of Science ®Google Scholar
• Hsieh PC, MacGillivray C, Gannon J, Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006;114:637-44
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-12
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70
   PubMed Web of Science ®Google Scholar
• Izzedine H, Brocheriou I, Rixe O, Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 2007;22:2411
   PubMed Web of Science ®Google Scholar
• Worns MA, Weinmann A, Pfingst K, Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009;43:489-95
   PubMed Web of Science ®Google Scholar
• Wu S, Chen JJ, Kudelka A, Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9:117-23
   PubMed Web of Science ®Google Scholar
• Henry TD, Annex BH, McKendall GR, The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-65
   PubMed Web of Science ®Google Scholar
• Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004;7:193-201
   PubMedGoogle Scholar
• Dimmeler S, Fleming I, Fisslthaler B, Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-5
   PubMed Web of Science ®Google Scholar
• He H, Venema VJ, Gu X, Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 1999;274:25130-5
   PubMed Web of Science ®Google Scholar
• Jin K, Zhu Y, Sun Y, Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002;99:11946-50
   PubMed Web of Science ®Google Scholar
• Neagoe PE, Lemieux C, Sirois MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 2005;280:9904-12
   PubMed Web of Science ®Google Scholar
• Gu JW, Manning RD Jr, Young E, Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in sprague-dawley rats. Am J Physiol Regul Integr Comp Physiol 2009;297:R142-8
   Google Scholar
• Machnik A, Neuhofer W, Jantsch J, Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009;15:545-52
   PubMed Web of Science ®Google Scholar
• Facemire CS, Nixon AB, Griffiths R, Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54(3):652-8
   Google Scholar
• Stachon A, Schluter T, Junker K, The secretion of endothelin-1 by microvascular endothelial cells from human benign prostatic hyperplasia is inhibited by vascular endothelial growth factor. Growth Factors 2004;22:281-9
   PubMed Web of Science ®Google Scholar
• Veronese ML, Mosenkis A, Flaherty KT, Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-9
   PubMed Web of Science ®Google Scholar
• Beldner M, Jacobson M, Burges GE, Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007;12:1178-82
   PubMed Web of Science ®Google Scholar
• Breccia M, Carmosino I, Russo E, Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005;74:121-3
   PubMed Web of Science ®Google Scholar
• Kong HH, Sibaud V, Chanco Turner ML, Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 2008;144:820-2
   PubMed Web of Science ®Google Scholar
• Man XY, Yang XH, Cai SQ, Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med 2006;12:127-36
   PubMed Web of Science ®Google Scholar
• Robert C, Soria JC, Spatz A, Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500
   PubMed Web of Science ®Google Scholar
• Torino F, Corsello SM, Longo R, Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6:219-28
   PubMed Web of Science ®Google Scholar
• Sato K, Yamazaki K, Shizume K, Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 1995;96:1295-302
   PubMed Web of Science ®Google Scholar
• Wang JF, Milosveski V, Schramek C, Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 1998;157:5-12
   PubMed Web of Science ®Google Scholar
• Suzuki K, Mori A, Saito J, Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/iodide symporter gene. Endocrinology 1999;140:5422-30
   PubMed Web of Science ®Google Scholar
• Gerard AC, Denef JF, Many MC, Relationships between cell division, expression of growth factors and microcirculation in the thyroids of Tg-A2aR transgenic mice and patients with Graves’ disease. J Endocrinol 2003;177:269-77
   PubMed Web of Science ®Google Scholar
• Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000;166:475-80
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Duda DG, Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23:8136-9
   PubMed Web of Science ®Google Scholar
• Takahashi M, Buma Y, Iwamoto T, Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988;3:571-8
   PubMed Web of Science ®Google Scholar
• Chiloeches A, Marais R. Is BRAF the Achilles’ heel of thyroid cancer? Clin Cancer Res. 2006;12:1661-4
   PubMed Web of Science ®Google Scholar